{"id":70747,"date":"2026-05-12T10:39:40","date_gmt":"2026-05-12T10:39:40","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70747"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"cagrilintide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/cagrilintide\/","title":{"rendered":"Cagrilintida"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es la cagrilintida?<\/h3>\n<p style=\"margin: 0;\"><strong>Cagrilintida<\/strong> (developmental code AM833) is a 37-amino-acid long-acting synthetic amylin analog developed by Novo Nordisk. It is the lead amylin-class peptide in current metabolic support and the partner compound in the CagriSema combination (cagrilintide + <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a>), now in late-stage Phase 3 trials for obesity and type 2 diabetes. Plasma half-life ~159 hours enables once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3 (cagrilintida; com\u00fanmente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">An\u00e1logo sint\u00e9tico de amilina de acci\u00f3n prolongada (p\u00e9ptido acilado de 37 amino\u00e1cidos; agonista del receptor de calcitonina\/amilina; c\u00f3digo de desarrollo de Novo Nordisk AM833)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4,981 Da (con acilaci\u00f3n con \u00e1cido di\u00e1cido graso C20 y puente disulfuro intramolecular)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estructura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">37 amino\u00e1cidos basados en la estructura de la amilina humana con sustituciones que reducen la agregaci\u00f3n formadora de amiloide, un puente disulfuro intramolecular Cys2\u2013Cys7 necesario para la uni\u00f3n al receptor, y una cadena acilada de \u00e1cido di\u00e1cido graso C20 unida mediante un espaciador \u03b3-Glu-OEG-OEG que promueve una fuerte uni\u00f3n reversible a la alb\u00famina s\u00e9rica para lograr la semivida semanal. Extremo C-terminal amidado.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para per\u00edodos de uso m\u00e1s cortos. Los p\u00e9ptidos acilados pueden disolverse m\u00e1s lentamente que p\u00e9ptidos no modificados m\u00e1s peque\u00f1os \u2014 permita un tiempo adicional de equilibraci\u00f3n.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es la Cagrilintida?<\/h2>\n<p><strong>Cagrilintida<\/strong> is a long-acting synthetic analog of amylin \u2014 a 37-amino-acid pancreatic peptide hormone co-secreted with insulin from beta cells and one of the principal endogenous regulators of postprandial glucose excursion, satiety signalling, and gastric emptying. Endogenous human amylin has a short plasma half-life (~13 minutes), poor pharmacokinetics, and a strong tendency to form amyloid aggregates (the same islet amyloid that accumulates in type 2 diabetic pancreas tissue). Cagrilintide was engineered by Novo Nordisk (developmental code AM833) to overcome each of these limitations: substitutions to reduce aggregation, an intramolecular disulfide bridge preserved for receptor binding, and a C20 fatty-diacid acyl chain attached via a \u03b3-Glu-OEG-OEG spacer that drives strong reversible binding to circulating serum albumin. The combined effect is a plasma half-life of approximately 159 hours (~6.5 days), enabling once-weekly subcutaneous dosing. Cagrilintide has a mature molecular weight of approximately 4,981\u00a0Da including the acyl chain and disulfide bridge. The intramolecular Cys2\u2013Cys7 disulfide is essential for receptor binding \u2014 reduction of this bond converts the peptide into an inactive linear form. The fatty-acid tether is one carbon longer than semaglutide&#8217;s C18 acyl chain, producing the long half-life through the same albumin-binding mechanism. Cagrilintide is the most advanced compound in the renewed wave of amylin-pathway pharmacology, with the lead clinical programme being the <strong>combinaci\u00f3n CagriSema<\/strong> \u2014 cagrilintida 2,4 mg + <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a> 2,4 mg semanales \u2014 que complet\u00f3 los ensayos de Fase 3 REDEFINE-1 (obesidad) y REDEFINE-2 (DT2) con reducciones de peso corporal de aproximadamente 20\u201323% durante 68 semanas. La cagrilintida no est\u00e1 <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a stand-alone agent or in combination. <\/p>\n<h2>Mecanismo de Acci\u00f3n \u2014 Agonismo del Receptor de Amilina en Sitios CNS y Perif\u00e9ricos<\/h2>\n<p>Lo que hace que la cagrilintida sea farmacol\u00f3gicamente distintiva de los agonistas de GLP-1 es que act\u00faa sobre un <strong>sistema de receptores completamente diferente \u2014 la familia de receptores de amilina\/calcitonina \u2014 mediante tres mecanismos principales<\/strong> documented in published studies:<\/p>\n<ul>\n<li><strong>Agonismo del receptor de amilina (AMY1, AMY2, AMY3) \u2014 circuitos de saciedad en el tronco encef\u00e1lico<\/strong> \u2014 Los receptores de amilina son heterod\u00edmeros del receptor de calcitonina (CTR) con prote\u00ednas modificadoras de la actividad del receptor RAMP1, RAMP2 y RAMP3, generando los subtipos de receptor AMY1, AMY2 y AMY3. El principal sitio de acci\u00f3n para la se\u00f1alizaci\u00f3n de saciedad es el \u00e1rea postrema en el tronco encef\u00e1lico \u2014 una de las pocas regiones del SNC que carece de barrera hematoencef\u00e1lica, permitiendo el acceso directo por parte de la amilina circulante y an\u00e1logos acilados como la cagrilintida. La activaci\u00f3n de los receptores AMY en el tronco encef\u00e1lico desencadena proyecciones vagales y noradren\u00e9rgicas al hipot\u00e1lamo, suprimiendo la ingesta de alimentos en una escala de tiempo por comida.<\/li>\n<li><strong>Supresi\u00f3n del glucag\u00f3n y retraso del vaciado g\u00e1strico<\/strong> \u2014 Adem\u00e1s de la saciedad central, el cagrilintida reproduce las acciones metab\u00f3licas perif\u00e9ricas de la amilina: la supresi\u00f3n dependiente de glucosa de la secreci\u00f3n de glucag\u00f3n de las c\u00e9lulas alfa pancre\u00e1ticas, la reducci\u00f3n de la producci\u00f3n hep\u00e1tica de glucosa posprandial y un retraso pronunciado del vaciado g\u00e1strico. El retraso en el vaciado g\u00e1strico refuerza la saciedad al extender la se\u00f1al de plenitud posprandial y reduce la magnitud de la excursi\u00f3n de glucosa posprandial. La taquifilaxia (desensibilizaci\u00f3n parcial) del retraso del vaciado g\u00e1strico se desarrolla durante semanas de ocupaci\u00f3n continua del receptor, paralelamente al patr\u00f3n del eje GLP-1.<\/li>\n<li><strong>Mecanismo complementario al GLP-1 \u2014 la l\u00f3gica de CagriSema<\/strong> \u2014 La justificaci\u00f3n cl\u00ednica para combinar cagrilintida con <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a> se basa en mecanismos no superpuestos. Los agonistas de GLP-1 act\u00faan predominantemente en las neuronas POMC del n\u00facleo arqueado hipotal\u00e1mico (regulaci\u00f3n de la ingesta de alimentos a trav\u00e9s del sistema central del apetito) y en las c\u00e9lulas beta pancre\u00e1ticas (secreci\u00f3n de insulina dependiente de glucosa). Los agonistas de la amilina act\u00faan predominantemente en los receptores AMY del \u00e1rea postrema del tronco encef\u00e1lico (refuerzo de la saciedad por comida) y en las c\u00e9lulas alfa pancre\u00e1ticas (supresi\u00f3n del glucag\u00f3n). Los dos mecanismos son aditivos en lugar de superpuestos, raz\u00f3n por la cual CagriSema produce efectos sobre el peso corporal en los ensayos de Fase 3 que se acercan a la magnitud de los triple agonistas <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> sin pasar por el receptor GIP o del glucag\u00f3n.<\/li>\n<\/ul>\n<p>The C20 fatty-diacid acylation at lysine (analogous to semaglutide&#8217;s C18 modification) drives reversible serum-albumin binding that produces the ~159-hour plasma half-life. The intramolecular Cys2\u2013Cys7 disulfide bridge maintains the bioactive conformation required for AMY-receptor binding \u2014 users must avoid vigorous shaking or freeze-thaw cycles that could disrupt the disulfide. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Cagrilintide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesidad y regulaci\u00f3n del peso corporal<\/strong> \u2014 preclinical DIO (diet-induced obesity) rodent models, body-composition (DEXA\/MRI), food-intake assays, energy-expenditure characterisation; canonical peptide for the renewed amylin-pathway pharmacology programme<\/li>\n<li><strong>Combined cagrilintide + GLP-1 (CagriSema) studies<\/strong> \u2014 estudios comparativos y combinados con <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a> en modelos de obesidad y diabetes tipo 2; disecci\u00f3n mec\u00e1nica de los efectos complementarios vs aditivos vs sin\u00e9rgicos sobre el peso corporal (Enebo et al., Lancet 2021; resultados de Fase 3 de CagriSema)<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 control gluc\u00e9mico, supresi\u00f3n del glucag\u00f3n, excursi\u00f3n de glucosa posprandial en modelos de roedores con dieta alta en grasas<\/li>\n<li><strong>Farmacolog\u00eda del receptor de amilina<\/strong> \u2014 selectividad del subtipo de receptor AMY1 \/ AMY2 \/ AMY3, se\u00f1alizaci\u00f3n dependiente de RAMP, potencia agonista comparativa en los receptores de calcitonina vs amilina<\/li>\n<li><strong>Brainstem satiety-circuit studies<\/strong> \u2014 activaci\u00f3n espec\u00edfica del receptor en el \u00e1rea postrema, mapeo de proyecciones vagales y noradren\u00e9rgicas, distinci\u00f3n de los mecanismos GLP-1 del n\u00facleo arqueado<\/li>\n<li><strong>Gastric emptying and postprandial physiology studies<\/strong> \u2014 tiempo de vaciado g\u00e1strico, din\u00e1mica de la glucosa posprandial, integraci\u00f3n del eje de las hormonas intestinales<\/li>\n<li><strong>Comparative incretin\/amylin peptide studies<\/strong> \u2014 comparativa con agonista simple de GLP-1 (<a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a>), agonista dual GIP\/GLP-1 (<a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a>), y agonista triple GLP-1\/GIP\/glucag\u00f3n (<a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a>) para efectos sobre el peso corporal, control gluc\u00e9mico y perfil de efectos secundarios.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja la cagrilintida en el panorama de los p\u00e9ptidos metab\u00f3licos, consulte <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> como el componente de la combinaci\u00f3n CagriSema, <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> como el comparador de doble receptor, y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> como el comparador de triple receptor. Explore el completo <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks Cagrilintide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, short-cycle titration studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, estudios multicohorte, menor coste por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 2.4\u00a0mg weekly (the CagriSema arm), so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Cagrilintide is a comparatively scarce peptide because of the structural complexity (disulfide bridge + acyl tether) and ongoing clinical development controls, which is reflected in the per-mg price relative to small synthetic peptides. <\/p>\n<h2>Comparativa \u2014 Cagrilintida vs Semaglutida<\/h2>\n<p>La cagrilintida y <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> son las dos mitades de la combinaci\u00f3n CagriSema \u2014 el principal compuesto cl\u00ednico en Fase 3 en la farmacolog\u00eda actual de la obesidad. Act\u00faan sobre sistemas de receptores completamente diferentes (amilina\/calcitonina vs GLP-1) y producen efectos complementarios desde el punto de vista mecan\u00edstico: refuerzo de la saciedad por el eje de la amilina y supresi\u00f3n del glucag\u00f3n por un lado, regulaci\u00f3n del apetito por el eje GLP-1 y secreci\u00f3n de insulina dependiente de glucosa por el otro. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cagrilintida<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Semaglutida<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Familia de receptores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Familia de receptores de amilina\/calcitonina (AMY1\/2\/3)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Receptor de GLP-1 (GLP-1R)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">31 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Objetivo principal en SNC<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c1rea postrema del tronco encef\u00e1lico<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00facleo arqueado hipotal\u00e1mico (neuronas POMC)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efectos perif\u00e9ricos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Supresi\u00f3n del glucag\u00f3n, vaciado g\u00e1strico retardado<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Secreci\u00f3n de insulina, supresi\u00f3n del glucag\u00f3n, vaciado g\u00e1strico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Anclaje de \u00e1cidos grasos<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C20 di\u00e1cido + \u03b3Glu-OEG-OEG<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C18 di\u00e1cido + \u03b3Glu-AEEA-AEEA<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vida media<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159 horas (~6,5 d\u00edas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~165 horas (~7 d\u00edas)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Referencia de marca<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">En investigaci\u00f3n (AM833; combinaci\u00f3n CagriSema)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ozempic \/ Wegovy \/ Rybelsus<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efecto sobre el peso corporal (monoterapia)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~10% (Fase 2 de monoterapia)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15% (ensayos STEP)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinado (CagriSema)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\" colspan=\"2\">Reducci\u00f3n del peso corporal del ~20\u201323% a 2,4 mg + 2,4 mg semanales (REDEFINE-1 Fase 3)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in the amylin axis specifically, cagrilintide is the canonical long-acting peptide. For studies interested in maximal body-weight effect via combination pharmacology, the CagriSema model (cagrilintide + <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a>) es la referencia principal. Para comparar con el enfoque de apilamiento de receptores adoptado por los multiagonistas de una sola mol\u00e9cula, consulte <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> (dual GLP-1\/GIP) y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (triple GLP-1\/GIP\/glucag\u00f3n). <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> store lyophilized vials refrigerated at 2\u20138\u00a0\u00b0C in original packaging for short-term working stock. For unopened long-term storage, freeze at \u221220\u00a0\u00b0C. Lyophilized cagrilintide is stable under refrigeration for up to 24 months and at \u221220\u00a0\u00b0C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder. Like other disulfide-bridged peptides, cagrilintide\u2019s receptor binding depends on the intact Cys2\u2013Cys7 bond \u2014 handling that disrupts the disulfide will degrade activity. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.1\u00a0mL delivers 250\u00a0mcg; ~1.0\u00a0mL delivers a clinical-equivalent 2.4\u00a0mg dose. Swirl gently \u2014 do <strong>ajuste<\/strong> shake \u2014 and allow 5\u201310 minutes for full dissolution. Acylated peptides dissolve more slowly than smaller unmodified peptides; do not rush the step. A correctly reconstituted solution should be clear and colourless with no visible particles. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> store refrigerated at 2\u20138\u00a0\u00b0C and use within 30 days for optimal stability. Do not freeze the reconstituted solution \u2014 freeze-thaw cycles degrade peptide integrity and can disrupt the Cys2\u2013Cys7 disulfide bond. Discard any vial showing cloudiness, precipitate, or discolouration. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is Cagrilintide used for in studies?<\/h3>\n<p>Cagrilintide is used in studies investigating the amylin\/calcitonin receptor axis, brainstem area-postrema satiety circuits, postprandial glucose physiology, gastric emptying, obesity and body-weight regulation, type 2 diabetes preclinical models, and especially combination pharmacology with GLP-1 agonists (the CagriSema study model with <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">semaglutida<\/a>). It is the most-cited long-acting amylin analog in current metabolic-peptide studies. The pharmaceutical-grade cagrilintide sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>What is CagriSema?<\/h3>\n<p>CagriSema is the developmental name for the fixed-dose combination of <strong>cagrilintide + semaglutide<\/strong> at 2.4\u00a0mg + 2.4\u00a0mg weekly. It is Novo Nordisk\u2019s lead Phase 3 obesity programme \u2014 the REDEFINE-1 and REDEFINE-2 trials reported body-weight reductions of approximately 20\u201323% over 68 weeks, putting CagriSema in the same effect-size range as triple-agonist <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">retatrutide<\/a> while taking a completely different mechanistic route (combination of two single-receptor agonists rather than a single multi-agonist molecule). Cagrilintide is the amylin half of this combination. <\/p>\n<h3>How is Cagrilintide different from Semaglutide?<\/h3>\n<p>The fundamental difference is the receptor system. Cagrilintide acts on the amylin\/calcitonin receptor family (AMY1, AMY2, AMY3) with primary central effects in the brainstem area postrema. Semaglutide acts on the GLP-1 receptor with primary central effects in the hypothalamic arcuate nucleus. The two are pharmacologically complementary, not competing \u2014 their combination in CagriSema produces additive body-weight effects greater than either alone. Both are long-acting peptides with C20 \/ C18 fatty-acid acylation enabling once-weekly dosing. <\/p>\n<h3>How is Cagrilintide different from Tirzepatide?<\/h3>\n<p>Tirzepatide is a single molecule that activates two receptors (dual GLP-1\/GIP agonist). Cagrilintide activates only the amylin\/calcitonin receptor family. For studies interested in body-weight magnitude beyond single-receptor GLP-1, tirzepatide takes the \u201creceptor-stacking in one molecule\u201d approach while CagriSema (cagrilintide + semaglutide) takes the \u201cseparate molecules in combination\u201d approach. The two strategies have produced comparable body-weight effect sizes in their respective Phase 3 trials. <\/p>\n<h3>What is the typical Cagrilintide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 0.16\u00a0mg and increasing through 0.3, 0.6, 1.2, and finally 2.4\u00a0mg maintenance weekly \u2014 the same dose used in the CagriSema combination. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 approximately 1.0\u00a0mL equals a 2.4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>Is Cagrilintide FDA approved?<\/h3>\n<p>No. Cagrilintide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as either a stand-alone agent or in the CagriSema combination. CagriSema Phase 3 trials (REDEFINE-1 obesity, REDEFINE-2 T2DM) have reported positive results but regulatory submission and review remain ongoing as of current literature. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar Cagrilintide?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para existencias de trabajo a corto plazo, o \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar en 30 d\u00edas. No congelar la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido y pueden alterar el puente disulfuro esencial Cys2\u2013Cys7. Proteger siempre de la luz directa. <\/p>\n<h3>\u00bfC\u00f3mo se reconstituye Cagrilintide?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no directamente sobre el liofilizado), agite suavemente y deje reposar entre 5 y 10 minutos para una disoluci\u00f3n completa (los p\u00e9ptidos acilados se disuelven m\u00e1s lentamente que los p\u00e9ptidos no modificados m\u00e1s peque\u00f1os). No <strong>ajuste<\/strong> Agitar el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora, sin part\u00edculas visibles. Para un vial de 5 mg + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries Cagrilintide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>\u00bfPor qu\u00e9 Cagrilintide es m\u00e1s caro que otros p\u00e9ptidos?<\/h3>\n<p>Cagrilintide is structurally complex (37 amino acids with an intramolecular disulfide bridge and a fatty-diacid acyl chain) and is a relatively recent compound still under active clinical development by Novo Nordisk. Both factors contribute to higher synthesis cost and constrained supply relative to mature small synthetic peptides like BPC-157 or TB-500. The per-mg price reflects these supply-and-complexity factors rather than any difference in studies utility. <\/p>\n<h3>Can Cagrilintide be paired with Semaglutide in studies?<\/h3>\n<p>Yes \u2014 this is the canonical CagriSema protocol and the lead Phase 3 clinical combination. Cagrilintide and semaglutide act on different receptor families (amylin\/calcitonin vs GLP-1) with non-overlapping central and peripheral mechanisms, producing additive body-weight effects substantially greater than either alone. The clinical fixed-dose ratio is 2.4\u00a0mg cagrilintide + 2.4\u00a0mg semaglutide weekly. <\/p>\n<h3>Does Cagrilintide cause side reported effects?<\/h3>\n<p>Like other satiety-axis peptides, the most consistent finding is gastrointestinal \u2014 nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4\u20138 weeks of continuous dosing as receptor tachyphylaxis develops. Because cagrilintide is the amylin analog and not a GLP-1, the gastrointestinal profile differs from semaglutide in pattern, but the magnitude is comparable in published clinical studies. Long-term safety data continues to accumulate from Phase 3 trials. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media de Cagrilintide?<\/h3>\n<p>Cagrilintide has a plasma half-life of approximately 159 hours (~6.5 days) following subcutaneous administration. The extended half-life is achieved by reversible binding to circulating serum albumin via the C20 fatty-diacid tether at lysine, which protects the peptide from renal clearance. The half-life is comparable to semaglutide&#8217;s ~165 hours, allowing both compounds to be co-dosed weekly in CagriSema studies without divergent pharmacokinetics. <\/p>\n<h3>How long does Cagrilintide take to show effects in preclinical studies?<\/h3>\n<p>Los efectos farmacodin\u00e1micos agudos sobre el vaciado g\u00e1strico y la saciedad por comida son detectables en horas tras la primera dosis. Los efectos en el peso corporal en modelos de roedores DIO suelen ser estad\u00edsticamente significativos tras 1\u20132 semanas de dosificaci\u00f3n semanal y contin\u00faan acumul\u00e1ndose hasta las 8\u201312 semanas. El efecto m\u00e1ximo en la composici\u00f3n corporal se desarrolla tras 16\u201324 semanas de dosificaci\u00f3n continua, reflejando la trayectoria de la Fase 3 humana en REDEFINE-1. <\/p>\n<h3>\u00bfPuedo pedir Cagrilintide para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda Cagrilintide a todo el mundo desde nuestra red de env\u00edo de p\u00e9ptidos dedicada. Los pedidos solo de p\u00e9ptidos califican para nuestro servicio de env\u00edo de p\u00e9ptidos independiente. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Satiety-Axis Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/semaglutide\/\"><strong>Semaglutida<\/strong><\/a> \u2014 Single GLP-1 agonist \u2014 CagriSema combination partner; canonical glycaemic and CV-studies comparator<\/li>\n<li><a href=\"\/es\/tirzepatide\/\"><strong>Tirzepatida<\/strong><\/a> \u2014 Agonista dual de GLP-1\/GIP \u2014 comparador de apilamiento de receptores en una mol\u00e9cula<\/li>\n<li><a href=\"\/es\/retatrutide\/\"><strong>Retatrutida<\/strong><\/a> \u2014 Triple GLP-1\/GIP\/glucagon agonist \u2014 multi-axis metabolic support<\/li>\n<li><a href=\"\/es\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrially-encoded peptide \u2014 AMPK and insulin sensitivity<\/li>\n<li><a href=\"\/es\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explora el panorama de combinaciones de p\u00e9ptidos metab\u00f3licos<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados de p\u00e9ptidos metab\u00f3licos que incluyen <a href=\"https:\/\/medsbase.com\/es\/semaglutide\/\">Semaglutida<\/a> (combinaci\u00f3n CagriSema), <a href=\"https:\/\/medsbase.com\/es\/tirzepatide\/\">Tirzepatida<\/a> (comparador dual de GLP-1\/GIP), y <a href=\"https:\/\/medsbase.com\/es\/retatrutide\/\">Retatrutida<\/a> (comparador triple agonista). Gu\u00eda comparativa: <a href=\"https:\/\/medsbase.com\/es\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide \u2014 triple agonista vs dual agonista<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 An\u00e1logo de amilina de acci\u00f3n prolongada (Novo Nordisk AM833)<br \/>\n\u2705 Agonista del receptor de amilina\/calcitonina<br \/>\n\u2705 Componente combinado de CagriSema con semaglutida<br \/>\n\u2705 Saciedad en el tronco encef\u00e1lico + supresi\u00f3n del glucag\u00f3n<br \/>\n\u2705 Dosificaci\u00f3n semanal (~159 horas de vida media)<\/p>\n<p><strong>Cagrilintida<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70938,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,5441],"class_list":["post-70747","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cagrilintide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70938"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70747"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70747"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70747"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}